TriangleEpcoritamab (NCT06672705)
Epcoritamab trial for Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder (NCT06672705). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with post transplant lymphoproliferative disorder, a lymphoma that can develop after an organ or stem cell transplant, that has come back or not responded to treatment.
The idea: epcoritamab is a bispecific antibody given as a shot under the skin. One end binds CD3 on T cells, and the other binds CD20 on B cells and some lymphoma cells, bringing immune cells to the cancer.
The study looks at safety and effectiveness.
This phase 1 study plans 26 patients. At the Ohio State University Comprehensive Cancer Center in Columbus, Timothy Voorhees leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.